BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Dose-escalation Study of Lupartumab Amadotin (BAY1129980)
Phase 1
Terminated
- Conditions
- Neoplasms
- Interventions
- Drug: Lupartumab Amadotin (BAY1129980)
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 69
- Registration Number
- NCT02134197
Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap
Phase 2
Completed
- Conditions
- Leiomyoma
- Interventions
- Drug: BAY1002670Drug: Placebo
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 309
- Registration Number
- NCT02131662
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer
Phase 1
Completed
- Conditions
- Solid Tumors Harboring NTRK Fusion
- Interventions
- First Posted Date
- 2014-04-25
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 75
- Registration Number
- NCT02122913
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
BAY86-5046 (Betaseron), Non Interventional Studies
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Interferon beta-1b (Betaferon, BAY 86-5046)Device: BETACONNECT auto-injector.
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 151
- Registration Number
- NCT02121444
Aflibercept in Polypoidal Choroidal Vasculopathy
Phase 4
Completed
- Conditions
- Neovascular Macular Degeneration
- Interventions
- Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)Other: Visudyne
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 333
- Registration Number
- NCT02120950
Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1298
- Registration Number
- NCT02117791
Copanlisib Mass Balance Study
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 6
- Registration Number
- NCT02119221
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 18
- Registration Number
- NCT02114658
Stivarga Regulatory Post-Marketing Surveillance Study in Korea
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 316
- Registration Number
- NCT02106858
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Phase 3
Completed
- Conditions
- Bronchiectasis
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 521
- Registration Number
- NCT02106832
© Copyright 2025. All Rights Reserved by MedPath